How to Diagnose LADA Diabetes
Test for islet autoantibodies (GAD65, IA-2, ZnT8, and insulin antibodies) in adults with diabetes who have clinical features suggesting autoimmune diabetes rather than typical type 2 diabetes.
Key Diagnostic Approach
The diagnosis of LADA requires demonstrating pancreatic autoimmunity in an adult who initially appears to have type 2 diabetes. Standardized islet autoantibody testing is recommended for classification of diabetes in adults who have phenotypic risk factors that overlap with type 1 diabetes 1.
Clinical Red Flags That Should Trigger Autoantibody Testing
Look for these specific features that distinguish LADA from typical type 2 diabetes:
- Younger age at diagnosis (typically <50 years, though can occur in elderly)
- Lean body habitus (BMI <25 kg/m²) 2, 3
- Unintentional weight loss 1
- Absence of clinical insulin resistance (no acanthosis nigricans, normal waist circumference)
- Progressive glycemic deterioration despite multiple oral agents 2, 4
- Rapid progression to insulin requirement (within months to few years)
- Personal or family history of autoimmune diseases (thyroid disease, celiac disease, etc.) 2
- Ketoacidosis or near-ketoacidosis 1
- Persistent glycemic instability with marked variability 3
Specific Laboratory Tests
Primary diagnostic tests:
- GAD65 antibodies (most commonly positive in LADA; >5 IU/mL is positive) 4
- IA-2 antibodies (insulinoma antigen-2) 2
- ZnT8 antibodies (zinc transporter 8) 2
- Insulin autoantibodies (if tested before insulin therapy initiated)
Supportive tests:
Critical Diagnostic Pitfall
The most common error is relying solely on C-peptide to rule out autoimmune diabetes. A "normal" C-peptide (e.g., 1.3 ng/mL in the reference range of 0.8-5.2 ng/mL) does NOT exclude LADA—if the value is in the lower end of normal and clinical features are atypical for type 2 diabetes, autoantibody testing must be performed 4. The case literature demonstrates that providers frequently miss LADA by accepting low-normal C-peptide as evidence against autoimmune diabetes.
Diagnostic Algorithm
- Identify clinical phenotype mismatch: Adult with "type 2 diabetes" who has any of the red flags listed above
- Order autoantibody panel: GAD65, IA-2, ZnT8 (and insulin antibodies if not yet on insulin)
- Measure C-peptide: To assess beta-cell reserve
- Interpret results:
Timing Considerations
Test early in the disease course when suspicion arises—autoantibodies may become undetectable in later stages as beta-cell destruction progresses 1. The presence of multiple autoantibodies indicates more rapid progression to insulin dependence 1, 5.
Why This Matters for Patient Outcomes
Correct diagnosis of LADA rather than type 2 diabetes fundamentally changes management—patients require insulin therapy rather than continued escalation of oral agents that will inevitably fail 2, 4. Delayed diagnosis leads to prolonged hyperglycemia, increased risk of diabetic ketoacidosis, and preventable complications 4. Early insulin initiation may help preserve remaining beta-cell function and achieve better long-term glycemic control 3.